Cyagen White Paper - SARS-CoV-2 Neutralizing Antibody and Vaccine Development

Though the current situation regarding COVID-19 is still severe, since July, many successes have been achieved on SARS-CoV-2 neutralizing antibody and Phase II clinical trials of SARS-CoV-2 vaccines. With the effort of scientists worldwide, results indicate that research will continue to make progress in the fight against COVID-19.

Herein, we discuss several frequently asked questions regarding both the design of the neutralizing antibody and the progress of vaccines for SARS-CoV-2. What is meant by neutralizing antibody research? What is current progress of SARS-CoV-2 vaccines? How do we verify the safety and efficiency of vaccines with animal models?

1. Neutralizing Antibody Research

• Coronavirus S protein is a key factor which determines virus virulence, tissue tropism, and host range - which have made it the main target of neutralizing antibody and vaccine design.
• The most effective neutralizing antibody was BD-368-2, which showed strong therapeutic and preventive effects on hACE2 transgenic mice infected with SARS-COV-2.
• In hACE2 mouse models, the administration of H014 can simultaneously reduce the SARS-CoV-2 virus titer and mitigate pathological changes in the lungs.

2. Development Progress of SARS-CoV-2 Vaccines

1. Overview of Immunizations and Vaccines
2. COVID-19 Vaccine Updates through July 2020
3. Understanding Antibody-Dependent Enhancement (ADE)
4. Risks of Antibody-Dependent Enhancement (ADE) of Coronaviruses

3. Applications of Animal Models to Evaluate Vaccine Safety

Download Free Copy of White Paper!

Cyagen hACE2 Mice: two main technologies, three strains, multiple targeting strategies - ONLY $300

Cyagen have used the proprietary TurboKnockout^® technology and optimized CRISPR-Pro Technology to carry out the development of humanized ACE2 mice base on three background strains: BALB/c, C57BL/6J and C57BL/6N, to meet the needs of different research applications for SARS-CoV-2 drug screening and vaccine development.